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Summary
When a patient needs general anesthesia for a surgical procedure, there are
certain requirements with which anesthesia must comply. Patients must be
properly anesthetized using hypnotics and analgesics. Also, muscle relaxa-
tion is required for intubation and for abdominal or intrathoracic surgery.
Muscle relaxation prevents surgery-related increases in muscle tone. Vola-
tile anesthetics influence the degree and time course of effect of neuromus-
cular blocking agents. The function of important clearing organs, like kid-
ney and liver, and diseases of the neuromuscular system, like myasthenia
gravis, also influence the requirement for neuromuscular blocking drugs.
Patients with myasthenia gravis are more sensitive to muscle relaxants.
This is thought to arise from a decreased acetylcholine receptor concentra-
tion at the neuromuscular junction. The neuromuscular junction, which is
the effect compartment for neuromuscular blocking agents, is selectively
affected. Therefore the myasthenic state offers unique possibilities to study
the potency and time course of effect of neuromuscular blocking agents,
because. The main goal of this study was to find a pharmacokinetic-
pharmacodynamic (PK-PD) model that would provide a better understand-
ing of the biophase kinetics, and particularly of the role of receptor density
in the pharmacology of neuromuscular blocking agents. Ultimately this
may lead to a safer and more rational use of neuromuscular blocking
agents.
Chapter I gives a general overview of the anatomy and physiology of the
neuromuscular junction. The mechanisms underlying neural activation of a
muscle are explained. The anatomy of the prejunctional nerve terminal, of
the synaptic cleft and of the postjunctional muscle cell membrane is de-
scribed. Also the physiology of neuromuscular transmission is reviewed,
with respect o acetylcholine synthesis and storage and release of acetylcho-
line following the arrival of an action potential at the nerve terminal and
the activation of the endplate leading to muscle contraction. The section
on pharmacology describes drugs with prejunctional effects, drugs that
have postjunctional effects, and drugs that have combined effects, like neu-
romuscular blocking agents and anticholinesterases. Methods of quantifi-
cation of the degree of neuromuscular transmission are mentioned. The
last part of this chapter reviews some dysfunctional states of the neuromus-
cular junction, caused by diseases like (congenital) myasthenia gravis and
the Lambert Eaton myasthenic syndrome, by poisoning with organophos-
phorous agents or animal toxins, and by the presence of atypical plasma
cholinesterase.
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Chapter II deals with the backgrounds of pharmacokinetic-
pharmacodynamic modeling. The relatively complex physiological model-
ing approach as well as the more simple mathematical compartmental
modeling approach are reviewed. Population pharmacokinetics and differ-
ent methods to model population data are summarized. Combining phar-
macokinetics and pharmacodynamics offers the opportunity of PK-PD
modeling. The gold standard, i.e. the link model proposed by Sheiner and
colleagues, is presented and circumstances are discussed under which this
model is unable to predict the time course of effect of neuromuscular
blocking agents adequately. Three examples are presented to illustrate the
shortcomings of the Sheiner model i.e., the poor prediction during the first
minutes after administration of a neuromuscular blocking agent, the inap-
propriateness to model a mivacurium-induced block, and the inability to
predict the PK-PD in myasthenia gravis. Finally, a new PK-PD model, i.e.
the unbound receptor model, is introduced and its performance in myas-
thenic PK-PD modeling is examined. The results are compared to those
obtained with another PK-PD model, taking into account the receptor con-
centration, the model proposed by Donati and colleagues.
Chapter III connects the introductory part to the experimental part, placing
the conducted studies in the context of this thesis.
Chapter IV describes the development of a new animal model, that enables
studying the biophase kinetics of neuromuscular blocking agents. This new
model should provide a way to study the pharmacodynamics of neuromus-
cular blocking agents with minimal interference of pharmacokinetic events.
The tibialis anterior muscle of a rat was dissected free from the other mus-
cles of the hind leg and the distal end was connected to a force transducer,
after which the skin was closed again to prevent heat and fluid loss. The
arterial and venous blood vessels were cannulated to provide a single pass
perfusion of the tibialis muscle with rat donor blood. The tibialis nerve
was prepaÍed free from the surrounding tissues and connected to a nerve
stimulator. During the experiment, the Íat was placed in a heated, thermo-
statically controlled chamber. To test this model for viability, blood sam-
ples taken after perfusion were examined, histological samples were re-
viewed and the response of the muscle to nerve stimulation was monitored.
In this chapter, also results are reported of some preliminary experiments
with neuromuscular blocking agents which differ in potency, and experi-
ments with different flow rates. After a stabilization period, an infusion
with rocuronium or pancuronium was started, until a stable neuromuscular
block of 90"Á was obtained. The infusion was then turned off. The time
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course of effect of the neuromuscular blocking agent was recorded and
analyzed. It was found that the potency of a neuromuscular blocking agent
had little or no influence on the onset and offset of the neuromuscular
block, while a higher blood flow to the muscle speeded up the rate of both
onset and offset of neuromuscular block. This is in contrast to findings in
in vivo studies in animals and humans. The difference between the rate of
onset or offset with higher flow illustrates the decisive role of pharmacoki-
netics on the time course of effect of neuromuscular blocking agents in
vivo.
In chapter V, this tibialis anterior model in rats is used to study the influ-
ence of a decreased acetylcholine receptor concentration on the time course
of effect of neuromuscular blocking agents. Two different myasthenic rat
models were used. The first model was an acute myasthenic model, in
which alpha-bungarotoxin was used to simulate a decreased acetylcholine
receptor state. Alpha-bungarotoxin binds irreversibly to the majority of
acetylcholine receptors, decreasing the number of acetylcholine receptors
available for acetylcholine and neuromuscular blocking agents at the neu-
romuscular junction. Also a more chronic model of myasthenia gravis was
used. Rats showed clinical features of myasthenía aÍter anti-bodies against
the acetylcholine receptor had been used. This could be confirmed by labo-
ratory analysis, comparing the acetylcholine receptor concentration of tibi-
alis anterior muscles of control rats and myasthenic rats. An infusion with
pancuronium or rocuronium was started until a stable 90oÁ block was
reached and the time course of effect was recorded. The recorded data
were analyzed using PkPdFit. Different PK-PD models were used. Finally,
the link model proposed by Sheiner and colleagues was compared to a new
PK-PD model, that takes into account the number of acetylcholine recep-
tors available for neuromuscular transmission. The latter model was found
to be more suitable to describe the observed changes in time course and
potency in these 'myasthenic' rats. Using PK-PD modeling, a decrease in
EC,n could be demonstrated, as reflected by the increased sensitivity and a
less steep concentration-effect relationship.
Chapter VI describes the development of a model for myasthenia gravis in
pigs, to test this new PK-PD model in a setting that would allow drawing
blood samples. Pigs were injected intramuscularly with the acetylcholine
receptor of the Torpedo californica (pacific electrical ray) and received a
second injection (boost) 2l days later. All pigs became myasthenic within a
week following the second injection. They showed loss of appetite and
food intake, and clinical signs of muscle weakness. During the PK-PD
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modeling study, rocuronium was infused at a slow rate, both in myasthenic
and in healthy controi pigs, to obtain a 90"Á neuromuscular block. At
predefined time poir-rts, blood was sampled to determine the rocuronium
concentration. A PK-PD analysis was performed, using the Sheiner model
and the unbound receptor model. Analysis revealed that solely a decrease
in receptor concentration could describe the observed differences in ro-
curonium time course of effect in myasthenic pigs, when compared to con-
trol pigs. The transport rate constant from the first compartment to the
effect compartment was different between control pigs and myasthenic
pigs. This may be attributable to a relatively hypovolemic state and a con-
comitant decreased cardiac output in myasthenic pigs when compared to
control pigs. Pharmacokinetic parameters were the same in both animal
groups.
In chapter VII, a PK-PD modeling study in humans was conducted, and the
performance of the unbound receptor model in humans was examined.
Eight myasthenic patients were studied, who were scheduled for thymec-
tomy and eight control patients, scheduled to undergo elective ear nose and
throat surgery or general surgery not requiring additional relaxation after
intubation. Rocuronium was administered by a short infusion at a prede-
fined rate to reach a neuromuscular block of at least 90%. ín both control
and myasthenic patients. The rate in the latter group was reduced to com-
pensate for a decreased requirement (25 pg/kg/min in myasthenic patients
versus 716.7 pglkglmin for control patients). At predefined points during
onset and offset of neuromuscuiar block, arterial samples were taken. Data
were analyzed with both the link model proposed by Sheiner and the un-
bound receptor model. Contrary to our findings in myasthenic pigs, solely
a decrease in receptor concentration could not provide a reasonable fit for
data obtained in these myasthenic patients. The exponential coefficient of
the relationship between the twitch height and the receptor concentration
in myasthenic patients had to be adjusted compared to that of controls.
This different exponential coefficient might be linked to interindividual dif-
ferences in the treatment of myasthenia gravis. The unbound receptor
model was able to provide a better fit of the time course of effect in myas-
thenic patients and a reasonably good fit in control patients.
Finally, in chapter VIII, we used the obtained PK-PD values to simulate the
behavior of a closed-loop infusion system, based on a proportional-
integral-constant (Pl+C)-controller in myasthenic patients. Based on a
measured variable for degree of paralysis the closed-loop infusion system
administers a muscle relaxant (in this case rocuronium) to a patient, in an
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effect-controlled manner (i.e. to a degree of neuromuscular block). In this
case a PlC-controller and twitch height after single twitch stimulation were
used to keep neuromuscular block at a predefined level. A controller was
designed for normal patients and myasthenic patients (both based on the
Sheiner and the Unbound Receptor model). The performance of each con-
troller was tested in both control and myasthenic patients. The parameter
set (control or myasthenic patients) as well as the PK-PD model (Sheiner or
Unbound Receptor) that were used to optimize such a controller have only
limited effect on the performance of the controller. The performance of a
PIC controller is good, regardless of the PK-PD model that is used, or the
patient group for which the controller is optimized.
It was concluded that the unbound receptor model is a useful model to be
applied in myasthenic patients or in the various animal models. If the
study is conducted in homogeneous groups (chapter IV and chapter V), the
unbound receptor model performs better than the Sheiner model. The un-
bound receptor model relates the observed time course of effect to the ace-
tylcholine receptor concentration. Furthermore, the model improves the
fitting results for data obtained in myasthenic patients. It does, however,
not improve PK-PD fitting in control patients. The major advantage of this
model is that it explains the observed changes in time course of effect and
potency of neuromuscular blocking agents in a more physiological way
than the Sheiner model. In the latter model, the increased sensitivity can be
accounted for by decreased model parameters, such as gamma and effective
concentration at 50yo effect, but there is no explanation as to why these
parameters are decreased. The unbound receptor model offers an explana-
tion for the observed changes in time course and potency in myasthenic pa-
tients, based on the decreased acetylcholine receptor concentration, that is
seen in myasthenic patients. The unbound receptor improves the PK-PD
fitting results, regardless of how the reduction of acetylcholine Íeceptor
concentration has been reached.
It may be interesting to test the unbound receptor model in burn patients,
which have an up-regulated number of acetylcholine receptors. The up-
regulation increases both junctional and extrajunctional receptors, and the
majority of the up-regulated receptors are of the fetal type which goes to-
gether with different binding, conducting and opening time characteristics.
It should be clear that only the junctional up-regulation may be reflected in
the unbound receptor model, whereas an increase of the extrajunctional
receptors will only influence the dose requirement.
